1. A method for decrypting web based content in a hybrid mobile application, the method comprising the steps of:
a computer receiving a first request to access encrypted content from a hybrid mobile application, and in response, the computer decrypting an encrypted secret key to expose the secret key using an asymmetric key algorithm and a decryption key of an asymmetric key pair for the asymmetric key algorithm; and
the computer decrypting the encrypted content using the secret key and a symmetric key algorithm.
2. The method of claim 1, further comprising the steps of:
the computer receiving a second request to access the encrypted content;
the computer determining that the secret key is cached on the computer; and
the computer decrypting the encrypted content using the secret key and a symmetric key algorithm.
3. The method of claim 1, further comprising the steps of:
the computer placing the encrypted content that has been decrypted in memory;
the computer receiving a notification that the encrypted content that has been decrypted is no longer needed by the hybrid mobile application, and
the computer removing the encrypted content that has been decrypted from memory.
4. The method of claim 1, further comprising the steps of:
the computer placing the encrypted content that has been decrypted in memory; and
the computer removing the encrypted content that has been decrypted from memory as the hybrid mobile application stops running.
5. The method of claim 1 further comprises the step of the computer reading the encrypted content that has been decrypted.
6. The method of claim 1, wherein the secret key comprises 256 bits.
7. A computer program product for decrypting web based content in a hybrid mobile application, the computer program product comprising:
one or more computer-readable tangible storage devices and program instructions stored on at least one of the one or more storage devices, the program instructions comprising:
program instructions to receive a first request to access encrypted content from a hybrid mobile application, and in response, program instructions to decrypt an encrypted secret key to expose the secret key using an asymmetric key algorithm and a decryption key of an asymmetric key pair; and
program instructions to decrypt the encrypted content using the secret key and a symmetric key algorithm.
8. The computer program product of claim 7, further comprising:
program instructions, stored on at least one of the one or more storage devices, to receive a second request to access the encrypted content;
program instructions, stored on at least one of the one or more storage devices, to determine that the secret key is cached on the computer; and
program instructions, stored on at least one of the one or more storage devices, to decrypt the encrypted content using the secret key and a symmetric key algorithm.
9. The computer program product of claim 7, further comprising:
program instructions, stored on at least one of the one or more storage devices, to place the encrypted content that has been decrypted in memory;
program instructions, stored on at least one of the one or more storage devices, to receive a notification that the encrypted content that has been decrypted is no longer needed by the hybrid mobile application, and
program instructions, stored on at least one of the one or more storage devices, to remove the encrypted content that has been decrypted from memory.
10. The computer program product of claim 7, further comprising:
program instructions, stored on at least one of the one or more storage devices, to place the encrypted content that has been decrypted in memory; and
program instructions, stored on at least one of the one or more storage devices, to remove the encrypted content that has been decrypted from memory as the hybrid mobile application stops running.
11. The computer program product of claim 7, further comprising program instructions, stored on at least one of the one or more storage devices, to read the encrypted content that has been decrypted.
12. The computer program product of claim 7 wherein the secret key comprises 256 bits.
13. A computer program product for encrypting web based content and packaging a hybrid mobile application, the computer program product comprising:
one or more computer-readable tangible storage devices and program instructions stored on at least one of the one or more storage devices, the program instructions comprising:
program instructions to receive a command to encrypt web based content and package a hybrid mobile application;
program instructions to create a secret key;
program instructions to encrypt the web based content using the secret key and a symmetric key algorithm;
program instructions to encrypt the secret key using an encryption key of an asymmetric key pair and an asymmetric key algorithm; and
program instructions to package the hybrid mobile application.
14. The computer program product of claim 13 further comprising program instructions, stored on at least one of the one or more storage devices, to sign the hybrid mobile application.
15. The computer program product of claim 14, wherein the program instruction to sign the hybrid mobile application comprises:
program instructions to retrieve the encryption key the asymmetric key pair; and
program instructions to create a digital signature on the hybrid mobile application using the encryption key.
16. The computer program product of claim 13, wherein the web based content comprises files of web based application code written in cross-platform languages.
17. The computer program product of claim 13 further comprising program instructions, stored on at least one of the one or more storage devices, to compile native application code for the hybrid mobile application.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. An isolated nucleic acid molecule selected from the group consisting of:
a) a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO: 1, or SEQ ID NO:3;
b) a nucleic acid molecule comprising a fragment of at least 1200 nucleotides of the nucleotide sequence of SEQ ID NO: 1, or SEQ ID NO:3;
c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO: 2; and
e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1, 3, or a complement thereof, under stringent conditions.
2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:
a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:3; and
b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
3. The nucleic acid molecule of claim 1 further comprising a vector nucleic acid sequence.
4. The nucleic acid molecule of claim 1 further comprising a nucleic acid sequence encoding a heterologous polypeptide.
5. A host cell which contains the nucleic acid molecule of claim 1.
6. The host cell of claim 5 which is a mammalian host cell.
7. A non-human mammalian host cell containing the nucleic acid molecule of claim 1.
8. An isolated polypeptide selected from the group consisting of:
a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:3;
b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1, SEQ ID NO:3, or a complement thereof under stringent conditions; and
c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 200 contiguous amino acids of SEQ ID NO:2.
9. The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:2.
10. The polypeptide of claim 8 further comprising a heterologous amino acid sequence.
11. An antibody which selectively binds to a polypeptide of claim 8.
12. A method for producing a polypeptide selected from the group consisting of:
a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2; and
c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1, SEQ ID NO:3, or a complement thereof under stringent conditions; the method comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.
13. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:
a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and
b) determining whether the compound binds to the polypeptide in the sample.
14. The method of claim 13, wherein the compound which binds to the polypeptide is an antibody.
15. A kit comprising a compound which selectively binds to a polypeptide of claim 8 and instructions for use.
16. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:
a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
17. The method of claim 16, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
18. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.
19. A method for identifying a compound which binds to a polypeptide of claim 8 comprising the steps of:
a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and
b) determining whether the polypeptide binds to the test compound.
20. The method of claim 19, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:
a) detection of binding by direct detecting of test compoundpolypeptide binding;
b) detection of binding using a competition binding assay;
c) detection of binding using an assay for 46980-mediated ligand binding.
21. A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
22. A method for identifying a compound which modulates the activity of a polypeptide of claim 8, comprising:
a) contacting a polypeptide of claim 8 with a test compound; and
b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
23. A method of modulating a pain response, comprising: contacting a cell with an agent that modulates the activity or expression of the polypeptide of claim 8 in an amount effective to modulate a pain response.
24. A method of modulating a pain response, comprising: contacting a cell with an agent that modulates the activity or expression of the nucleic acid of claim 1 in an amount effective to modulate a pain response.
25. A method of evaluating a subject under treatment for a pain disorder, comprising:
providing a sample from the subject;
assessing the expression of a 46980 nucleic acid or 46980 polypeptide; and
comparing the expression to a reference level, wherein a change relative to the reference level is indicative of the efficacy of the treatment.
26. A method of diagnosing a neurological disorder in a subject, comprising:
providing a sample from the subject;
determining the expression or activity of a 46980 nucleic acid or a 46980 polypeptide in the sample;
comparing the expression or activity to the corresponding level in a sample from a normal subject or a cohort of normal subjects, wherein a difference is indicative of the neurological disorder.
27. A method of modulating the function or viability of a 46980-expressing cell, comprising:
contacting the 46980-expressing cell using a compound that binds a 46980 polypeptide in an amount effective to modulate the function or viability of the 46980-expressing cell.
28. The method of claim 27, wherein the compound induces killing of the 46980-expressing cell.
29. The method of claim 28, wherein the compound is an antibody or a soluble neurexin.
30. The method of claim 29, wherein the compound is attached to a a cytotoxin, a cytotoxic agent and a radioactive metal ion.
31. The method of claim 27, wherein the 46980-expressing cell is a neural cell.
32. A method of labeling a 46980-expressing cell in a subject comprising administering a compound that binds the polypeptide of claim 8; and detecting the localization of the compound in the subject, wherein the compound is labeled or recognizable by a labeling entity.